CD14基因-260A/G位点多态性与前列腺癌易感性的研究

目的研究CD14基因-260A/G位点多态性与前列腺癌易感性的关系。方法提取168例前列腺癌患者和208例对照组的外周血DNA标本,应用聚合酶链反应-连接酶特异检测技术（polymerase chain reaction-ligase detection reaction,PCR-LDR）分析前列腺癌患者CD14-260A/G位点多态性,比较不同基因型和前列腺癌易感性的关系,并探讨不同基因型与前列腺癌患者年龄、体重指数（body mass index,BMI）、吸烟、饮酒及肿瘤家族史的关系。结果总体来说CD14基因-260A/G多态性与前列腺癌易感性之间无显著相关性（P=0.284,OR=1.27,95%CI=0.82～1.94）;饮酒（P=0.003）和肿瘤家族史（P〈0.001）与前列腺癌的发生密切相关;在分层分析中,年龄〈70岁的男性携带CD14-260G（AG＋GG）等位基因者能增加前列腺癌的易感性（P=0.011,OR=2.93,95%CI=1.28～6.70）。结论 CD14基因-260A/G位点多态性在总体上与前列腺癌易感性无显著相关性,但在年龄小于70岁男性中,携带有CD14-260G等位基因者患前列腺癌的危险性却明显增高。     

基因测序筛选前列腺癌患者PCA3(DD3)基因外显子多态性

目的 筛查前列腺癌患者PCA3基因外显子单核苷酸多态性位点,初步探讨PCA3基因多态性与前列腺癌的相关性.方法 采用基因测序法对41例前列腺癌(PCa)患者和40例良性前列腺增生(BPH)患者进行PCA3基因外显子SNP位点的筛选,对筛选到的sNP位点进行前列腺癌的相关性分析.结果 PcA3基因外显子1、外显子3、外显子4区域均未检测到基因多态性位点,PCA3基因外显子2区域存在1个SNP位点(A→C),基因型分别为AA型、AC型、CC型,该位点的基冈型频率和等位基因频率与前列腺癌存在相关性(P<0.05).结论 基因测序可有效筛选到PCA3基因外显子的SNP位点,PCA3基因外显子2基因多态性可能与前列腺癌发病风险有关.     

非HLA基因单核苷酸多态性对造血干细胞移植后巨细胞病毒感染的影响

目的 探讨非HLA基因单核苷酸多态性(SNP)对造血干细胞移植后巨细胞病毒(CMV)感染的影响.方法 对2008年7月至2011年12月接受异基因造血干细胞移植的受者及其相应供者64例进行研究.采用聚合酶链反应-序列特异性寡核苷酸探针和测序方法检测髓过氧化物酶基因(MPO)、甘露糖结合凝集素基因(MBL)、CD14基因和血管紧张素转换酶(ACE)基因的SNP,结合CMV pp65检测结果,比较CMV阳性组和CMV阴性组ACE、CD14、MPO、MBL基因SNP的差异.结果 ACE 16内含子基因多态性分布:DD型14例(10.9％),ID型72例(56.3％),Ⅱ型42例(38.8％);CD14-159位基因多态性分布:CC型18例(14.1％),CT型81例(63.3％),TT型29例(22.7％);MPO-463位点基因多态性分布:G型100例(78.1％),A型2例(1.6％),GA型26例(20.3％);MBL启动子-550位基因多态性分布:H型28例(21.9％),HL型73例(57.0％),L型27例(21.1％);MBL启动子-221位基因多态性分布:Y型87例(68.0％),YX型38例(29.7％),X型3例(2.3％);MBL外显子1区基因多态性分布:A型94例(73.4％),AB型32例(25.0％),B型2例(1.6％).CMV阳性组和CMV阴性组供、受者ACE、CD14-159位点、MPO-463位点、MBL启动子-221以及外显子1区基因单核苷酸多态性相比较,差异均无统计学意义;但CMV阳性组供者MBL-550位点HL基因频率明显增高,与阴性组比较,差异有统计学意义.结论 供者MBL的单核苷酸多态性对造血干细胞移植后CMV感染有影响.     

CYP1A2基因多态性与前列腺癌的相关性研究

目的:评价CYP1A2基因单核苷酸多态性(SNPs)与前列腺癌分期分级的相关性。方法:对253例良性前列腺增生(BPH)患者与206例去势前列腺癌患者CYP1A2基因中rs2069514-3859(A>G)位点及rs2069525-1707(C>T)位点进行基因测序,并对各基因表型与前列腺癌的分期分级相关性进行统计学分析。结果:BPH及去势前列腺癌患者的两种CYP1A2单核苷酸多态性的发生率无明显差异(P>0.05),其基因多态性与前列腺癌的病理分期均无相关性(P>0.05);但rs2069525-1707(C>T)中含C等位基因型的前列腺癌Gleason评分多在7分以下(P=0.030,OR=4.658,95%CI:1.222～17.754)。结论:CYP1A2基因的SNPs与前列腺癌的病理分级之间可能有一定的相关性,但其发生机制及临床意义有待进一步证实及研究。     

一个影响前列腺癌中L-plastin启动子转录活性的多态性位点的成功鉴定

目的研究已发现的前列腺癌中L-plastin启动子一个多态性位点对其转录活性的影响和意义。方法扩增前列腺癌细胞株LNCaP中L-plastin启动子序列,发现在距离转录起始点-1751上存在多态性位点T后,利用定点突变技术构建文献报道的启动子序列质粒(-1751C),测定含-1751T质粒和含-1751C质粒的荧光素酶活性。用巢式PCR扩增前列腺癌细胞株和癌组织中该位点序列,并进行单链构象多态性分析。结果成功构建L-plastin启动子,并发现一个位于-1751的多态性位点(C/T);成功构建启动子序列含-1751C质粒;荧光素酶活性测定表明(-1751C)质粒启动子转录活性为(-1751T)质粒的4~5倍,2者受到雄激素刺激后活性均升高;单链构象多态性分析表明该位点多态性普遍存在于前列腺癌患者和细胞株。结论鉴定了一个普遍存在于前列腺癌的L-plastin基因启动子的多态性位点,含有不同碱基位点的启动子的转录活性明显不同。     

类固醇5a-还原酶Ⅱ基因89位点多态性与亚洲男性前列腺癌易感性的Meta分析

目的 探讨类固醇5a-还原酶Ⅱ (SRD5a2)基因89位点多态性与亚洲男性前列腺癌易感性的关系。方法 检索PubMed、中国知网、万方、维普数据库,获取SRD5a2基因89位点多态性与亚洲男性前列腺癌易感性的病例-对照研究。以前列腺癌组与对照组人群基因型分布的OR值为效应指标,采用固定或随机效应模型进行合并分析,并进...     

前列腺癌及前列腺上皮内瘤13号染色体等位基因杂合性缺失分析

目的　探讨原发性前列腺癌及高级别前列腺上皮内肿瘤 (PIN) 13号染色体等位基因杂合性缺失 (LOH)及其意义。　方法　经显微切割技术获取前列腺癌及PIN标本各 10例。提取DNA ,采用PCR及微卫星多态性技术 ,对 13号染色体上 14个微卫星标志位点LOH进行检测。　结果　 10例原发性前列腺癌中 7例 13号染色体上至少有一个位点检测到LOH。 13q14及 13q12～ 13为两个高频LOH区。 10例PIN中 13号染色体的 14个位点均未检测到LOH。　结论　前列腺癌中存在 13号染色体的高频LOH区 ,乳腺癌易感基因 (BRCA2 )、视网膜母细胞瘤基因 (RB1)及位于附近的肿瘤抑制基因可能与前列腺癌的发生发展有关     

巨噬细胞清道夫受体单核苷酸多态性与前列腺癌易感及患者预后的相关性分析

目的 探讨分析巨噬细胞清道夫受体(MSR1)单核苷酸多态性与前列腺癌易感及患者治疗预后的相关性.方法 选择2017年3月至2019年5月在本院治疗的前列腺癌患者103例设为前列腺癌组,再选取同期在本院健康体检的男性受试者97例设为对照组.检测两组受试者MSR1基因rs918位点及rs1904577位点的基因多态性分布情...     

苏、皖地区汉族人群DNA修复基因XRCC1 Arg399Gln多态性与前列腺癌易感性的关系

目的:研究中国苏、皖汉族人群DNA修复基因X线修复交叉互补基因1(X-ray repair cross complementing group 1,XRCC1)Arg399Gln多态性,并探讨其在吸烟、饮酒与前列腺癌易感性关系中的影响。方法:采用病例-对照研究,提取207例前列腺癌患者(病例组)和235例非肿瘤、非前列腺疾病患者(对照组)外周血中基因组DNA,应用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)分析病例组和对照组的XRCC1基因Arg399Gln位点的多态性,比较不同基因型与前列腺癌易感性的关系,并探讨吸烟、饮酒等因素在其中的影响。结果:XRCC1第399密码子Arg/Gln基因型的个体其前列腺癌发病风险是Arg/Arg基因型的1.55倍(OR=1.55,95%CI:1.01~2.39),携带399Gln等位基因(Arg/Gln及Gln/Gln)的个体发生前列腺癌的风险性是Arg/Arg基因型的1.61倍(OR=1.61,95%CI:1.07~2.44)。在重度吸烟(吸烟指数≥20)人群中,携带399Gln等位基因的个体发生前列腺癌的风险性是Arg/Arg基因型的1.94倍(OR=1.94,95%CI:1.02~3.71)。在浅吸烟(吸烟仅入嘴中)人群中,携带399Gln等位基因的个体发生前列腺癌的风险性是Arg/Arg基因型的2.44倍(OR=2.44,95%CI:1.02~5.80)。结论:XRCC1 Arg399Gln位点多态性可能对前列腺癌遗传易感性产生影响,Arg/Gln、Gln/Gln可能是前列腺癌的易感基因型,并和吸烟在前列腺癌的发病中有一定的协同作用。     

维生素D受体基因Taq I位点多态性与亚洲男性前列腺癌易感性的Meta分析

目的 探讨维生素D受体(VDR)基因Taq I位点多态性与亚洲男性前列腺癌易感性的关系.方珐检索PubMed、中国知网、万方数据库、维普中文科技期刊,获取VDR基因Taq I位点多态性与亚洲男性前列腺癌易感性的病例-对照研究.以前列腺癌组与对照组人群基因型分布的OR值为效应指标,采用固定或随机效应模型进行合并分析,并进行偏倚评估,应用STATA10.0软件进行统计学处理.结果 共纳入文献10篇,研究10项,累计前列腺癌病例1 141例,对照1 685例.与等位基因T相比,C等位基因合并的OR(95%CI)为0.81(0.70～0.94);与野生基因型TT相比,CT和CC+CT基因型合并的OR(95%CI)分别为0.86(0.74～1.01)和0.84(0.73～0.97).结论 VDR基因Taq I位点变异可能会降低亚洲男性个体患前列腺癌的危险性.     

肿瘤坏死因子相关凋亡诱导配体启动子区-716位点单核苷酸多态性与前列腺癌危险因素的研究

目的：研究肿瘤坏死因子相关凋亡诱导配体（TRAIL）启动子区-716A／G位点单核苷酸多态性（SNP）与影响前列腺癌危险因素的关系。方法：应用聚合酶链反应-连接酶特异检测技术（PCR-LDR）分析186例前列腺癌患者TRAIL基因-716位点的多态性,比较不同基因型与前列腺癌患者诊断时的前列腺癌特异性抗原（PSA）、Gleason评分和TNM临床分期的关系。结果：TRAIL-716G（AG＋GG）等位基因与PSA、Gleason评分和TNM临床分期均具有显著的相关性（adjustedOR=0．04,0．07,0．08;95％CI：0．01～0．14,0．02～0．29,0．03～0．21）。结论：TRAIL-A716G（AG＋GG）等位基因可能与前列腺癌预后有关,携带TRAIL-716G（AG＋GG）等位基因的前列腺癌患者可能预后较好。     

前列腺癌血清PSA、f/tPSA与Gleason评分、临床分期的相关性研究

目的 探讨前列腺癌病人血清PSA、f/tPSA（血清游离PSA与总PSA的比值）与前列腺癌Gleason评分、临床分期的相关性.方法 查阅我院1998年1月～2005年6月归档的前列腺癌病历资料,建立临床资料数据库,对归档病理切片进行Gleason评分.采用Spearman等级相关分析,分析血清PSA、f/tPSA与前列腺癌Gleason评分、临床分期的关系.结果 269例前列腺癌中,前列腺癌PSA值与Gleason评分呈正相关（r=0.361,P＜0.01）,与前列腺癌临床分期呈正相关（r=0.586,P＜0.01）;f/tPSA与Gleason评分有弱负相关（r=-0.128,P=0.035）,与前列腺癌临床分期呈负相关（r=-0.226,P＜0.01）.结论 血清PSA、f/tPSA与前列腺癌预后密切相关的指标临床分期和Gleason评分有关.     

Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital

OBJECTIVE: To determine if it is possible to exclude staging bone scans in a greater proportion of patients if more consideration is given to T stage and Gleason score, as recent guidelines from the National Institute of Clinical Excellence state that routine staging bone scans for prostate cancer are unnecessary in patients with a prostate specific antigen level (PSA) of < 10 ng/mL and Gleason scores of < 8. PATIENTS AND METHODS: We identified a cohort of consecutive patients with untreated prostate cancer who had a staging isotope bone scan between 1 January 1995 and 31 December 2000, who were not on hormone therapy, who had their PSA estimated within 30 days of the scan, and who had histologically confirmed prostate cancer on biopsy reviewed at the Royal Marsden. Data were analysed according to Gleason score, major Gleason grade, clinical T-stage and PSA level. RESULTS: In all, 420 patients were identified who fulfilled the criteria for inclusion; 67 scans (16%, 95% confidence interval, CI, 13-20%) were positive. Of the 187 scans taken in patients with a PSA level of 相似文献   

前列腺跨膜上皮抗原在前列腺癌组织中的表达及与PSA的关系

目的 探讨前列腺癌组织中前列腺跨膜上皮抗原(STEAP)表达及与前列腺特异性抗原(PSA)的关系.方法 采用免疫组织化学染色法检测65例前列腺癌(其中T1 9例、T2 14例、T317例、T4 25例,高分化癌37例、中分化癌12例、低分化癌16例)组织标本中STEAP的表达,引入阳性灰度值概念判定染色强度;分析STEAP表达水平与肿瘤分期、分级、血清PSA及游离PSA/总PSA(f/t PSA)比值的关系.结果 65例患者血清PSA值为(27.65±8.34)ng/ml,f/t PSA为0.15±0.04.STEAP阳性表达63例,其中T1 7例、T2 14例、T3 17例、T4 25例,高分化癌37例、中分化癌11例、低分化癌15例.T1、T2、T3、T4前列腺癌组织中STEAP表达平均阳性灰度值(Gs)分别为26.8%、45.6%、62.3%、76.5%,高、中、低分化癌组织中STEAP表达平均Gs分别为71.2%、52.8%、34.4%.STEAP表达与肿瘤分期呈正相关(r=0.67,P<0.01);随着Gleason评分的增高,STEAP表达逐渐降低(P<0.01);STEAP表达与患者血清PSA无明显相关性(r=0.21,P>0.05),而与f/t PSA比值呈负相关(r=-0.83,P<0.01).结论 STEAP可作为判断前列腺癌浸润深度、分化程度的指标之一.     

X线交错互补修复基因1和核苷酸剪切修复基因多态性与前列腺癌发病风险的相关性

目的 探讨DNA损伤修复基因X线交错互补修复基因1(XRCCI)、核苷酸剪切修复基因(XPD)基因多态性与前列腺癌发病风险的关系. 方法 以358例前列腺癌患者和312例健康对照者为研究对象,采用聚合酶链反应一限制性片段长度多态技术检测XRCC1 C26304T、G28152A和XPD A35931C位点基因型,以非条件logistic回归分析计算比值比(OR)及95%可信区间(CI),评估不同基因型与前列腺癌风险之间的相关性. 结果 前列腺癌组XRCC1 28152位点AA基因型者47例(13.1%),对照组24例(7.1%),携带此基因型者患前列腺癌风险显著增加(OR 1.924,95%CI=1.126～3.288,P=0.017).2组间XRCC1 C26304T和XPD A35931C位点基因型分布差异无统计学意义.3个基因位点联合分析结果 显示,个体携带XRCCI 28152AA型及XPD 35931AC+CC型者发生前列腺癌风险显著增加(OR=3.087,95%CI 1.081～8.813;OR=3.376,95%CI 1.067～10.683,OR 3.216,95%CI=1.439～7.188,P=0.004).以患者年龄、PSA值、Gleason评分以及临床分期分层分析结果 显示,携带XRCC1 28152AA及XPD 35931AC+CC基因型者发病年龄明显低于携带野生基因型者(P<0.05). 结论 中国汉族人群XRCCl和XPD基因多态与前列腺癌发病有关,尤其是较年轻者.     

Role of radical prostatectomy in patients with prostate cancer of high Gleason score

BACKGROUND: The routine use of serum prostate-specific antigen (PSA) testing combined with digital rectal examination has lowered tumor volume and clinical-pathological stage of men undergoing radical prostatectomy. Therefore, we may identify more men with poorly differentiated tumors of early clinical stage. In order to identify those who may benefit from radical prostatectomy, we evaluated known prognostic variables in patients with prostate cancer of high Gleason score (8-10). METHODS: Of 652 patients who underwent a radical prostatectomy as monotherapy for clinically localized prostate cancer between March 1991-December 1995, 84 patients with prostatectomy specimen Gleason score 8-10 tumors were identified. Clinical-pathological data were obtained from our prostate cancer database. Gleason score, PSA level, margin status, pathologic stage, and tumor volume were analyzed as general prognostic variables for disease-free survival (DFS). Follow-up ranged from 13-84 months (median, 36.2). Biochemical recurrence was defined as a postoperative PSA elevation greater than 0.4 ng/ml. RESULTS: The DFS for patients with Gleason score 8-10 and pathologically organ-confined disease was 62.5%. DFS was 56.2% for patients with PSA < or =10 ng/ml, compared to 19.2% for patients with serum PSA >10 ng/ml (P = 0.009). Patients with nonspecimen-confined disease (positive margins) had a DFS rate of 26.6% vs. 55% for patients with specimen-confined disease (negative margins) (P = 0.009). On multivariable analysis, only preoperative PSA < or =10 ng/ml (P = 0.02) and surgical margin status (P = 0.04) were significant predictors of DFS. CONCLUSIONS: Surgical margin status and preoperative serum PSA level are independent predictors of DFS for patients with high Gleason score prostate cancer treated by radical prostatectomy as monotherapy. Patients with poorly differentiated prostate cancer treated surgically at an early stage can have a favorable prognosis, especially if negative surgical margins are obtained. A preoperative serum PSA level < or =10 ng/ml carries the greatest likelihood of achieving prolonged DFS in this group of patients.     

Clinical stage T1c prostate cancer: pathologic outcomes following radical prostatectomy in black and white men

BACKGROUND: The incidence of prostate cancer in black men is 50% to 70% higher than among age-matched white men. Black men have a twofold higher mortality rate and overall tend to have higher serum prostate-specific antigen (PSA) levels than white men. To determine whether racial differences exist in men whose prostate cancer was diagnosed based solely on an elevated serum PSA level, we compared clinical and pathologic features in black and white men undergoing radical prostatectomy (RP) for clinical stage T1c prostate cancer. METHODS: We used a prospectively collected database to identify all men undergoing RP for clinical T1c prostate cancer between July 1995 and October 2000. A total of 129 consecutive men (56 black men and 73 white men) were compared for age at diagnosis, serum PSA level, biopsy Gleason score, pathologic stage, RP specimen Gleason score, incidence of lymph node metastasis, and incidence of positive surgical margins. RESULTS: Statistically significant differences were not found by race in patients' ages, serum PSA levels, biopsy Gleason score, pathologic stage, incidence of lymph node metastases, or incidence of positive surgical margins. The RP specimen Gleason score was more heterogeneous in black men than white men (P=0.02). CONCLUSIONS: Racial differences in the incidence and mortality rate of prostate cancer are well known, but differences in the clinical and pathologic features between black and white men with prostate cancer identified solely based on an elevated serum PSA level with negative results on digital rectal examination (clinical stage T1c ) have been poorly studied. Our results suggest that men with clinical stage T1c prostate cancer have similar clinical and pathologic findings regardless of race. These results suggest that early-detection programs using serum PSA testing for prostate cancer in black men potentially can result in improvements in prostate cancer outcomes in this high-risk group.     

Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population

PURPOSE: The SRD5A2 gene codes the steroid 5-reductase type II, a critical mediator of androgen action, and the V89L and A49T polymorphisms of this gene may be associated with a distinct enzyme activity. We explored the association among these polymorphisms and the risk of prostate cancer or benign prostatic hyperplasia (BPH) in a Japanese population. MATERIALS AND METHODS: This study included 302 patients with prostate cancer, 228 with BPH and 243 male controls. V89L and A49T polymorphisms were analyzed by the polymerase chain reaction restriction fragment length polymorphism method. Genotypes were evaluated by electrophoresis on agarose gel. RESULTS: For the V89L polymorphism there were no significant differences in genotype frequencies in patients with prostate cancer and controls (p = 0.071) or in patients with BPH and male controls (p = 0.219). However, males with the VV or VL genotype were at significantly increased risk for prostate cancer compared with those with the LL genotype (adjusted OR 1.69, 95% CI 1.07 to 2.65, p = 0.024). The risk of BPH in males with the VV or VL genotype was not significantly elevated in comparison with those with the LL genotype (adjusted OR 1.37, 95% CI 0.85 to 2.20, p = 0.194). The V89L variant was not associated with the grade or stage of prostate cancer, or with patient age. For the A49T polymorphism all subjects had the AA genotype. CONCLUSIONS: The V allele of the V89L polymorphism in the SRD5A2 gene may dominantly increase the risk of prostate cancer.